Cerluten vs MOTS-c

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene expression regulatory mechanisms. Like other Khavinson bioregulator peptides, cerluten is proposed to reach target neuronal cells via amino acid transporter uptake — including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT) — and to modulate transcriptional activity in aging or damaged neural tissue. Published research on Khavinson-class ultrashort peptides has characterized intracellular transport via POT and LAT carriers and demonstrated gene expression regulatory effects across multiple tissue types, providing the class-level mechanistic framework within which cerluten's neuronal effects are proposed. Cerluten has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals. Cerluten dosing and respiratory applications Cerluten is classified as a bronchial tissue bioregulator in the Khavinson peptide research tradition, proposed to act on bronchial epithelial cells via amino acid transporter uptake and modulate gene expression related to respiratory tissue maintenance and oxidative stress response in aging airways. Preclinical and observational research in Eastern European clinical settings has examined cerluten in contexts of chronic bronchitis, age-related decline in respiratory function, and COPD support, with proposed mechanisms including anti-inflammatory gene regulation and bronchial epithelial cell cytoprotection. Standard Khavinson-class dosing protocols use oral capsule formulations in 10–20 day cycles at 5–10mg per cycle (divided doses), followed by rest intervals — consistent with the gene-regulatory rather than continuous-receptor-occupancy mechanism proposed for this peptide class. Independent peer-reviewed clinical trial evidence specific to cerluten is limited; efficacy data comes primarily from Khavinson Institute publications and observational reports. Cerluten is available from specialty Eastern European supplement and peptide vendors and is not approved by the FDA or EMA as a pharmaceutical. It is distinct from Chonluten, which targets lung parenchyma rather than bronchial epithelial tissue.

Mitochondria-derived peptide that translocates to nucleus under stress; activates AMPK pathway, regulates AICAR and folate-methionine cycle

MOTS-c (mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the 12S ribosomal RNA gene of the mitochondrial genome, secreted from mitochondria into the cytoplasm and circulation in response to metabolic stress and exercise, where it functions as a hormonal signal regulating nuclear gene expression to promote metabolic homeostasis and insulin sensitivity. MOTS-c translocates from mitochondria to the nucleus under metabolic stress conditions, where it activates AMPK-dependent pathways that increase glucose uptake in skeletal muscle and adipose tissue, reduce lipid accumulation, and modulate one-carbon metabolism through the AICAR-AMPK-folate cycle — effects that parallel some metabolic actions of physical exercise and metformin. Foundational research published in Cell Metabolism characterized MOTS-c as a mitochondrially encoded metabolic hormone that promotes metabolic homeostasis, reduces obesity, and improves insulin resistance in preclinical models, and subsequent work has analyzed its broad metabolic regulatory role and clinical potential as an insulin-sensitizing agent. MOTS-c is a research compound with no regulatory approval in any jurisdiction; while circulating MOTS-c levels in humans have been characterized and decline with age, no clinical trials have established safety or efficacy for exogenous MOTS-c administration. MOTS-c dosage protocol: No human clinical trial has established a reference dosing protocol for exogenous MOTS-c administration. Animal research protocols examining MOTS-c metabolic effects have used subcutaneous injection as the primary delivery route, with doses determined by body weight in rodent models. Human circulating MOTS-c levels have been measured in exercise and aging studies — endogenous levels decline with age and rise transiently with aerobic exercise — but these observations do not establish a target dose for supplemental administration. Research interest focuses on MOTS-c as a potential exercise mimetic and insulin sensitizer, with investigation of dosing frequency and timing relative to metabolic challenge or fasted states. MOTS-c is a research compound; there are no approved human dosing guidelines for any indication.